Dr. Chapa’s Clinical Pearls.-logo

Dr. Chapa’s Clinical Pearls.

Anchor FM

Relevant, evidence based, and practical information for medical students, residents, and practicing healthcare providers regarding all things women’s healthcare! This podcast is intended to be clinically relevant, engaging, and FUN, because medical education should NOT be boring! Welcome...to Clinical Pearls.

Relevant, evidence based, and practical information for medical students, residents, and practicing healthcare providers regarding all things women’s healthcare! This podcast is intended to be clinically relevant, engaging, and FUN, because medical education should NOT be boring! Welcome...to Clinical Pearls.


United States


Anchor FM


Relevant, evidence based, and practical information for medical students, residents, and practicing healthcare providers regarding all things women’s healthcare! This podcast is intended to be clinically relevant, engaging, and FUN, because medical education should NOT be boring! Welcome...to Clinical Pearls.




Nix RhoGAM® Under 12 weeks?

Anti-D immune globulin has been advocated for use in appropriate patients since the 1970s. Historic data showed that 0.1ml of fetal D+ blood was all that was required to potentially sensitize an Rh negative mother. New data is questioning whether this prophylaxis is required in all cases of threatened miscarriage/abortion in early pregnancy, or if a more selective approach is appropriate. In this episode, we will highlight a soon to be released “Questioning Clinical Practice” commentary from...


Fragile X Syndrome: Targeted or Universal Screening?

Fragile X Syndrome is the most common inherited form of intellectual disability, and the most common single gene cause of Autism Spectrum Disorder. It is also responsible for some cases of premature ovarian insufficiency. Do you recall the difference between a Fragile X “pre-mutation” versus the full mutation? Should we do universal screening for this as part of expanded maternal carrier testing, or should this be a targeted screening approach? Although we covered maternal carrier screening...


Weed and Breastfeeding: Yay or Nay.

Marijuana is the most commonly used federally illegal drug in the United States; its use among pregnant and lactating women is on the rise. Is breast-feeding contraindicated with marijuana use? It is difficult to separate marijuana use from several confounding variables, leading to conflicting data in print. Is marijuana use and breast-feeding compatible? A patient friendly article on Parents.com, released on November 23, 2022 seems to imply just that. In this episode, we will review the...


The Mouth’s Effect on Pregnancy

Several cohort studies and meta-analysis have shown a direct association between poor oral health and adverse pregnancy outcomes. The key driver for this association is systemic inflammation. In this episode, we will review the ADA, ACOG, and CDC data on how maternal oral health can influence pregnancy outcomes. Although this association is pretty strong, remember that association does not necessarily prove causation. We will explain this in this episode.


🧠Your Brain on Gratitude 🙏 🧠❤️

Happy Thanksgiving, Podcast family! As we gather with family, friends, and loved ones… Let’s make the practice of gratitude a daily habit, not some thing that we do just once a year. There is real science on the art and practice of gratitude! In this brief episode, we will remind ourselves that gratitude is not just “something we do” on Thanksgiving, but really should be our way of life. We will cover gratitude’s effect on neurochemistry and it’s activation of critical brain centers....


Wimbledon, The Period, and Lack.

On November 17, 2022 Wimbledon showed a major head nod to women’s health. Do you know what that was? Nonetheless, this recognition of menstruation is just one small move forward, noting that Period Poverty is still widespread right here in the US. In this episode, we will review “Wimbledon, the period, and lack”.


🪷 The Lotus Birth Request 🪷

“The Lotus Birth”… Although first described back in the 1970s, this birthing trend is gaining popularity today mainly because of social media. Is this practice evidence-based? Is it safe? There are real concerns here which have spurred several professional organizations and societies to issue HARSH warnings about this practice. In this episode, we will review the origins and current state of “the Lotus Birth”. We will also review the tragic case of Baby Harlow Eden. We will wrap up this...


SLE and APS: ASA, LMW Heparin, or Both?

Systemic Lupus Erythematosis is several-fold more common in women than in men. As it primarily targets reproductive age women, identification of and proper management of patients with associated antiphospholipid antibodies is crucial to improve maternal and neonatal outcomes. In this episode, we will review the 2019 ACR diagnostic criteria for SLE and review the management of SLE patients with/without antiphospholipid antibodies and with/without antiphospholipid antibody syndrome.


NPO in Labor? No!

The idea of keeping women “Nil per os” (NPO) during labor traces back to the 1940s with the pivotal work of Dr. Curtis Mendelson. His work on “aspiration pneumonitis” has kept women NPO during labor up to present day. But is this still evidence-based? Is it risky to allow women to have PO intake during an otherwise uncomplicated labor course? In this episode we will walk through history and provide an updated view on the risks and benefits of this historic practice.



TXA was first found to reduce maternal morbidity at time of established postpartum hemorrhage in the WOMAN trial (2017). Since then, evidence has grown to include TXA as a prophylactic agent to prevent postpartum hemorrhage. Despite its known effectiveness in BOTH the prevention and treatment of postpartum hemorrhage, there is a renewed global warning regarding this medication. In this episode, we will review the WHO and FDA warning regarding the misapplication/inadvertent intrathecal use of...


Maternal Carrier Screening: What it is and isn’t.

Maternal carrier screening (either pan-ethnic or expanded carrier panel) is recommended by the ACOG and SMFM. Ideally, this is done pre-conception or with the first pregnancy. Did you know that in August 2022 the ACOG added an additional test for universal maternal carrier screening? Does this maternal carrier screen include BRCA? In this episode we will cover what maternal carrier screening is, and what it is not.


Dense Breasts on MMG: Part 2

Katie Couric recently described her path to her diagnosis of breast cancer, urging women with “dense breast tissue” to get supplemental breast imaging. Do these supplemental imaging tests improve overall survival? In this session, we will review the statements of 4 professional societies/organizations regarding the use of supplemental breast imaging for women with dense breasts who have no additional breast cancer risk factors and are asymptomatic.


Dense Breasts on MMG? What to do (Part 1)

Dense breasts can decrease the sensitivity of screening mammogram (MMG). Some US states have mandated reporting of breast density on MMG, while the rest of the states report on dense breasts voluntarily as a standardized reporting system. What supplemental breast imaging tools are advised as a follow up in these patients? Does the ACOG support supplemental breast imaging in average risk patients? What about the USPSTF? In this session we will do a deep dive into this common MMG description...


CSection ERAS: DC Foley?

The Enhanced Recovery After Surgery guidelines were birthed (no pun intended) as a way to curb post-op morbidity from colorectal surgery. In 2019, CSection ERAS guidelines were published in the AJOG. Despite widespread agreement that ERAS is valuable, one aspect of the guideline is controversial: timing of Foley removal. Should the Foley be removed immediately after C-section? Should an indwelling bladder catheter be used at all? Let’s dive into this topic now.


Save the Pitocin! Safe to stop Pit once in Active Phase?

The United States is currently facing an oxytocin shortage. How long this medication shortage is projected to continue is not clear. In an attempt to curb unnecessary use of oxytocin, is it safe to consider stopping oxytocin after induction, once the active phase of labor is reached? Is there data to support the practice? And what about using oxytocin for first trimester D&C? Is that evidence-based? In this session, we will review the data regarding discontinuation of oxytocin once the...


Tips for ABOG’s Oral Boards (and LIFE!)

We are in ABOG Oral Board season! 😳😊 Did you know that the national pass rate for first time takers of the OBGYN oral board is 90%! That’s good news. Do you know what the common mistakes made by the 10% who do my pass are? In this session we will cover the common missteps made by candidates during their oral boards, and highlight 5 tips for a successful oral board encounter. These tips are also applicable for ANY healthcare provider navigating their healthcare career. 😊😊


Finger-sticks (CBG) for GDM DX?

In 1964, John O’Sullivan published his original research describing abnormal cut off values following an oral glucose challenge in pregnancy. O’Sullivan laid the foundation for screening and diagnosis of gestational diabetes. We have learned a lot since that 1964 publication. In this session, we will review a new meta-analysis coming to print in November 2022 comparing the 1-step with the 2-step oral glucose tolerance test. We will also summarize data on point of care glucometers (capillary...


Is FSH Helpful for Perimenopausal AUB? (ABOG Prep for Rishi)

The ACOG and FIGO have 2 main “boxes” for AUB: 1. AUB in reproductive age women, and 2. postmenopausal bleeding. But AUB in the Menopausal Transition could be its own “box”. Is serum FSH a helpful test for AUB in the menopausal transition? In this episode we will cover this clinically relevant ABOG Oral Board prep question.


Hattie’s Hep B Vaccine in Pregnancy Clarification

Hattie… with these kind of insights, you are going to ROCK your oral boards in the next 72 hours! We are cheering you on! 👏👏👏👏


OB Vaccines: The Sequel!

Recently, we reviewed the 3 vaccines generally recommended for every woman, in each pregnancy. But as they often say on late night commercials, “but wait… There’s more!” In this session, we will review 3 separate vaccinations which are applicable in special populations. Do you know which 3 they are? In this session our special guest, Carley Hager (3rd year medical student), will help us review the ACOG recommendations.